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Abstract 
Background. The main goal of this study was to assess frequency, clinical correlates 
and independent predictors of fatigue in a homogenous cohort of well-defined glioblastoma 
patients at baseline prior to combined radio-chemotherapy.  
Methods. We prospectively included 65 glioblastoma patients at postsurgical baseline 
and assessed fatigue, sleepiness, mean bedtimes, mood disturbances and clinical 
characteristics such as clinical performance status, presenting symptomatology, details on 
neurosurgical procedure, tumor location and diameter as well as pharmacologic treatment 
including antiepileptic drugs, antidepressants and use of corticosteroids. Data on fatigue and 
sleepiness were measured with the Fatigue Severity Scale and the Epworth Sleepiness Scale, 
respectively, and compared to 130 age- and sex-matched healthy controls.  
Results. We observed a significant correlation between fatigue and sleepiness scores 
in both patients (r = 0.26, p = 0.04) and controls (r = 0.36, p < 0.001), but only fatigue 
appeared to be much more common in glioblastoma patients then in healthy controls (48% 
vs. 11%, p < 0.001), but not the frequency of sleepiness (22% vs. 19%, p = 0.43). Female sex 
was associated with increased fatigue frequency among glioblastoma patients, but not among 
control subjects. Multiple linear regression analyses identified depression, left-sided tumor 
location and female sex as strongest associates of baseline fatigue severity. 
Conclusions. Our findings indicate that glioblastoma patients are frequently affected 
by fatigue already at baseline, suggesting that factors other than those related to radio- or 
chemotherapy are of significant impact, in particular depression and tumor localization.  
Keywords   Fatigue; glioblastoma; sleepiness; depression 
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Introduction 
Glioblastoma is the most common primary brain tumor in adults, with an estimated 
incidence of about 3 per 100,000 inhabitants / year in Europe and North America.
1
 The 
standard of care for newly diagnosed glioblastoma, subsequent to surgery, comprises 
radiotherapy with concomitant temozolomide followed by adjuvant temozolomide. In the 
study defining this treatment regimen, median survival was limited to 15 months,
2
 and in a 
population-based analysis of more than 10,000 glioblastoma patients, median survival was 
reported to be only 12 months.
3
  
Independent of any treatment, fatigue is a common symptom in cancer patients in 
general as well as in primary brain tumor patients, with an estimated prevalence of 50 to 90% 
and 40 to 70% respectively.
4,5
 Cancer-related fatigue is defined by the National 
Comprehensive Cancer Network (NCCN) as a distressing, persistent, subjective sense of 
physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer 
treatment that is not proportional to recent activity and that interferes with usual functioning.
6
 
The patients themselves indicate fatigue as one of the most distressing symptom related to 
cancer and its treatment,
7
 and it is a strong predictor of decreased patient satisfaction, health-
related quality of life (QoL), and may represent one of the key reason for discontinuing 
treatment.
8-10
 Nevertheless, fatigue is believed to be underdiagnosed and underestimated in 
cancer patients despite its possible impact on treatment compliance.
4,11
 As a consequence, 
some groups have questioned, whether the standard treatment for glioblastoma is justified in 
view of the limited benefit on survival and the severity of associated symptoms.
12
 
However, compared to other tumor types, namely breast and lung cancer, rather few 
studies have addressed the problem of fatigue in glioblastoma patients in depth, and several 
limitations have to be mentioned. First, despite large differences in underlying neurobiology, 
treatment procedures and prognosis, many groups have included patients with all sorts of 
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primary brain tumors.
5,13
 Second, baseline data are often missing, in particular in studies 
using a cross-sectional design.
5
 As a consequence, fatigue was mainly assessed as a treatment 
complication, thereby failing to acknowledge the primary impact of the tumor itself and other 
treatment-independent factors.
14
 Third, considering the advances of modern radiation 
techniques, the results of many older series cannot be directly compared with the current 
situation. Finally, while many validated fatigue questionnaires are available,
9,15
 the large 
majority of neurooncological studies identified and quantified fatigue in a very rudimental 
way, using the Visual Analogue Scale (VAS) or one single fatigue item appearing in tools 
such as the European Organisation for Research and Treatment of Cancer (EORTC) QoL 
questionnaire, the M. D. Anderson Symptom Inventory–Brain Tumor Module or the 
Symptom Distress Scale.
9,12,16-18
 
Thus, in this prospective study we aimed at examining frequency and predictors of 
fatigue severity in a homogeneous cohort of glioblastoma patients at baseline prior to 
combined radio-chemotherapy. For this goal, we used the Fatigue Severity Scale (FSS), 
which has been identified as the most widely adopted fatigue questionnaire in clinical 
practice and has been validated for a variety of neurological diseases.
15,19,20
 In addition, we 
explored the evolution of fatigue, sleepiness and mood disorders during and after combined 
radio-chemotherapy.  
 
Patients and Methods 
  This prospective, longitudinal study was conducted as a collaboration of the 
Departments of Neurology, Oncology and Radiation Oncology of the University Hospital of 
Zurich, Switzerland, between October 2008 and October 2012. The study protocol was 
approved by the Ethics Committee of the Canton of Zurich, Switzerland, specialized 
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subcommittee for Psychiatry, Neurology, Neurosurgery (Project E-43/2007), and informed 
consent was obtained by all patients prior to enrollment. 
Patients and control subjects. We prospectively included 65 patients with newly 
diagnosed and histologically proven glioblastoma, corresponding to an estimated 60-65% of 
all eligible glioblastoma patients of the acquisition period. Patients aged ≥18 years 
undergoing postoperative standard radio-chemotherapy were eligible.
2
 They had to be fluent 
in German language. The patients were examined clinically and by questionnaires at three 
different time points: 1) 28 ± 7 days after the initial neurosurgical procedure (1 day prior to 
the first radiation), 2) at the time of the last radiation and 3) prior to the initiation of the 
adjuvant chemotherapy. Overall, the study period captured the first ten weeks of 
postoperative standard treatment.  
As control group we included 130 healthy and age- and sex-matched subjects using a 
1:2 case-control design. The controls were selected from a previously published cohort of 454 
healthy subjects, which we used in our original validation study of the German version of the 
Fatigue Severity Scale (FSS).
19
 
Clinical assessment and questionnaires. Demographic variables included age, sex and 
educational status (defined as highest degree attained). We ascertained several tumor 
characteristics, including type of neurosurgical procedure (biopsy, partial, complete or 
unclear resection), tumor topography and brain magnetic resonance imaging based tumor 
diameter. To elucidate whether the presenting symptomatology affects fatigue severity, we 
divided the medical history in seizure, motor weakness, cognitive deficit, 
headache/nausea/vomiting, apathy/asthenia, visual deficit, and accidental finding. Seizure 
type was further classified in partial, generalized, complex-focal, and unclassified. To 
estimate the influence of pharmacological treatment, we included at each time point details 
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on anticonvulsive drugs, antidepressants, anxiolytics, CNS stimulants, hypnotics, and 
whether or not patients received corticosteroids, including the dose of the steroids. Clinical 
performance status was assessed by the Karnofsky Performance Score (KPS), with 100% 
indicating perfect physical health and 0% death. As mentioned earlier, we measured fatigue 
by means of the FSS. This self-administered questionnaire comprises 9 items exploring 
fatigue severity in different situations during the past week, and the final score ranges from 1 
to 7, with the latter value indicating maximal fatigue. The presence of clinically significant 
fatigue was defined as a FSS score ≥ 4.0. The FSS has robust psychometric properties and 
has been validated for various neurological disorders but not yet for glioblastoma patients. 
We therefore performed a reliability statistic in our cohort, revealing an excellent internal 
consistency as reflected by a Cronbach’s α of 0.94.21 We used the German version of the 
Epworth Sleepiness Scale (ESS) for assessment of sleepiness; a score of ≥ 10 indicates 
EDS.
22
 We also determined the prevalence of overlap between fatigue and EDS, which was 
the case when patients presented both a FSS score ≥ 4.0 and an ESS score ≥ 10. Sleep need 
was estimated using information on mean bed times. We arbitrarily defined mean bedtimes ≥ 
10 hours as “long bedtimes”, probably indicating increased sleep need per 24 hours (i.e. 
hypersomnia). Finally, for evaluation of anxiety and depression, we used the German version 
of the Hospital Anxiety and Depression Scale (HADS). It is a well-validated questionnaire 
suitable for cancer populations as it contains only nonphysical symptoms of both anxiety and 
depression. Participants indicate their agreement with each item on a scale ranging from 0 to 
3. The questionnaire has two subscales for anxiety and depression, each consisting of 7 items. 
A score of > 10 is considered to indicate overt anxiety or depression.
23,24
 
Data analysis and statistics. We used SPSS (version 19.0) for statistical analysis. 
Group data are described by means, standard deviations (SD), and confidence intervals (95% 
CI). To compare mean values of FSS and ESS scores between glioblastoma patients and 
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control subjects, we used Student’s t test; χ2-test was used to compare the frequency of 
fatigue and EDS between the two groups. Longitudinal differences of scores were assessed 
using Student’s paired t test. We applied the Cronbach α statistics to calculate the internal 
consistency of the FSS in glioblastoma patients. To identify predictors of fatigue severity at 
baseline, we performed a multiple linear regression analysis with FSS score as dependent 
variable. Among the set of potential predictor variables (age, gender, education, KPS, ESS, 
bedtimes, anxiety and depression scores, tumor localization and use of steroids or 
antidepressants), we evaluated each variable for an estimated effect of ≥ 0.2 or ≤ -0.2 on the 
outcome score fatigue severity and a p-value < 0.05 in a univariate comparison. Those 
predictor variables fulfilling the two criteria were included in the multiple linear regression 
model. Significance was accepted at p < 0.05. 95% confidence intervals (CI) for mean 
differences between the groups were additionally presented when group differences were 
significantly different from zero. 
 
Results 
  Characterization of glioblastoma patients. We included 65 glioblastoma patients, of 
whom 44 patients (68%) were male. Mean age was 57.3 ± 10.1 years. The tumor was 
localized in the left brain hemisphere in 28 patients (43%), in the right hemisphere in 31 
patients (48%), and bilateral in 6 patients (9%). A majority of tumors affected the fronto-
temporal lobes (57%) as compared to the parieto-occipital lobes (31%), basal ganglia (5%) or 
multiple sites (8%). 
Comparison between glioblastoma patients and controls. Glioblastoma patients had 
significantly higher FSS scores (3.9 ± 1.7 vs. 2.8 ± 1.0, 95% CI 0.74 - 1.49, p < 0.001) and 
fatigue frequency (48% vs. 11%, p < 0.001), and significantly longer bedtimes (8.8 ± 1.2h vs. 
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7.7 ± 0.9h, 95% CI 0.76 - 1.39, p < 0.001) than controls, whereas ESS scores and the 
prevalence of EDS was similar (Table 1). FSS and ESS scores were significantly correlated 
in both glioblastoma patients (r = 0.26, p = 0.04) and control subjects (r = 0.36, p < 0.001). In 
glioblastoma patients, overlap of both fatigue and EDS was observed in 15%, while “isolated 
fatigue” was much more common (32%) than “isolated EDS” (6%) (Fig. 1). Conversely, we 
observed more controls with “isolated EDS” (14%) than “isolated fatigue” (5%) (p < 0.001).  
Comparison of glioblastoma patients with and without fatigue. Prior to radiotherapy, 
almost half of all glioblastoma patients suffered from fatigue. Compared to those without 
fatigue, glioblastoma patients with fatigue revealed a higher prevalence of EDS (32% vs. 
12%, p = 0.04), spent more time in bed (95% CI 0.13 - 1.32, p = 0.02) and were more 
depressed (95% CI 0.78 - 4.04, p = 0.005) (Table 2). In addition, gender distribution differed 
significantly: of totally 21 female glioblastoma patients, 14 had fatigue (67%), while only 
39% of all male patients had fatigue (p = 0.03). Of note, fatigue prevalence was similar in 
female and male controls (12% vs. 10%, p = 0.49). Finally, glioblastoma patients affected by 
a tumor in the left brain hemisphere appeared to suffer more frequently from fatigue than 
those with right-sided tumors (Table 3). Patients with left-sided tumor localization were also 
more prone to anxiety and depression. On the other hand, we did not observe any group 
differences concerning educational status, presenting symptomatology, seizure type, use of 
antiepileptic drugs or corticosteroids nor extent of tumor resection.      
Predictors of fatigue severity in glioblastoma patients. Using a multiple linear regression 
model, we identified higher HADS-D depression score (estimated effect = 0.16 per one unit 
increase in depression score, p = 0.004), left-sided tumor location (estimated effect = -0.88, p 
= 0.002) and female sex (estimated effect 0.89, p = 0.02) as significant associates of fatigue 
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severity at baseline prior to radio-chemotherapy (Table 4). The adjusted r-squared and the 
multiple r-squared of our final model were 0.29 and 0.32, respectively.  
Evolution of fatigue, EDS and mood disorders. Unfortunately, drop-out rate was 
rather high: of the included 65 GBM patients, only 46 and 38 patients filled out all 
questionnaires during and after radio-chemotherapy, respectively. Mean values for FSS and 
ESS scores, mean bedtimes, anxiety and depression scores of the HADS-D and KPS did not 
show significant changes at subsequent time points (Fig. 2).  
 
Discussion 
Our prospective study demonstrates that fatigue is a prominent pre-treatment 
symptom in patients with newly diagnosed and operated glioblastoma, reaching a prevalence 
of 48% compared to only 11% among healthy control subjects. Surprisingly, our data 
represent the first controlled assessment of fatigue frequency in a selected and homogeneous 
cohort of glioblastoma patients, and measured with a specific and validated fatigue 
questionnaire. Although direct comparison is obviously hampered by major methodological 
differences, our finding roughly matches the reported 40-70% fatigue prevalence among 
patients with primary brain tumors.
5,9,14
 On the other hand, we had found higher fatigue 
prevalence in patients with other neurological disorders such as multiple sclerosis (69%), 
idiopathic Parkinson’s disease (59%), episodic migraine (54%, unpublished data) or previous 
ischemic stroke (49%), always using the FSS.
19,20
  
Fatigue in patients with primary brain tumors has repeatedly been reported in relation 
to radiotherapy.
13,25,26
 In contrast, our study challenges the view that fatigue in glioblastoma 
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patients represents mainly a complication of radio- and / or chemotherapy, because the 
prevalence of fatigue was highly already prior to radio-chemotherapy. Therefore, the 
contribution of toxicity from radio-chemotherapy to fatigue is probably only one single factor 
among many others. In addition, the longitudinal assessment of fatigue, sleepiness and mood 
disturbances during and after radio-chemotherapy did not show significant changes, which 
might reflect, however, a bias due to the high drop-out rate. On the other hand, it’s 
conceivable that the toxic effect of radio-chemotherapy on fatigue severity was obscured in 
our cohort by the additional presence of many other fatigue-inducing factors. Of related 
interest is our observation that pharmacological treatment, including antiepileptic drugs, 
antidepressants or corticosteroids, was not associated with fatigue. This is in contrast to a 
recent work of Struik et al., who reported an increase of fatigue severity under antiepileptic 
drugs and corticosteroids among patients with low-grade glioma.
27
  
While fatigue was more than 4times more prevalent in glioblastoma patients than in 
control subjects, the frequency of excessive daytime sleepiness was similar (22% vs. 19%). 
Fatigue and sleepiness are commonly regarded as two distinct symptoms, but they present 
substantial overlap and presumably, at least to some extent, also similar pathophysiology.
28
 
Our finding is surprising, because increased frequency of sleepiness is indeed common in 
many neurological disorders with prominent fatigue. For instance, we found excessive 
daytime sleepiness in 48% of patients with idiopathic Parkinson’s disease and 38% of 
traumatic brain injury survivors, while other groups reported an even higher prevalence.
20,29
 
Degenerative or trauma-induced disruption of arousal-promoting structures in the rostral 
brainstem and hypothalamus may cause both fatigue and sleepiness, and this assumption is 
increasingly supported by neuropathological evidence.
30-32
 On the other hand, fatigue is a 
complex symptom, influenced by a large variety of factors, and the composition of these 
contributing factors differs most likely between neurological disorders commonly associated 
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with high fatigue burden. Thus, it’s tempting to speculate whether the selective increase of 
fatigue but normal prevalence of sleepiness may shed some light on the underlying etiology 
of glioblastoma-related fatigue. Of interest in this context, the discrepant prevalence of 
fatigue and sleepiness is reminiscent of patients with mood disorders, who often suffer from 
fatigue and insomnia, while sleepiness is not a consistent complaint.
33
 In the same line, using 
multiple regression analyses we could identify depression as independent predictor of fatigue 
severity at baseline. To the best of our knowledge, this is the first study to highlight this 
important association between fatigue severity and depression in glioblastoma patients, while 
similar correlations have been reported in breast cancer patients but never in patients with 
primary brain tumors.
34,35
  
Anxiety and depression represent normal emotional reactions to the diagnosis of 
glioblastoma, and they are significant and independent contributors to fatigue severity. 
However, as emphasized by the overview of Litofsky and Resnick and further corroborated 
by our observations, other factors have to be considered.
36
 Of note, fatigue, anxiety and 
depression all appeared to be more common in glioblastoma patients with left-sided tumors 
compared to those with right-sided tumors, and left-sided tumor location was consistently 
identified as independent predictor of fatigue severity. Indeed, there is some evidence 
indicating that patients with left hemispheric lesions are prone to depressive reactions, 
whereas patients with right hemisphere lesions often show indifferent emotional 
reactions.
33,38,39
 Likewise, Klein et al. found significant impairment of attentional and 
executive functioning in patients with left-sided high-grade glioma compared to right-sided.
40
 
However, several studies failed to observe any association between depression and 
hemispheric laterality of gliomas.
41
 Data on depression in ischemic stroke provide a similarly 
inconsistent picture. Few studies suggested a higher prevalence of depression in left-sided 
ischemic stroke, but other studies could not confirm a significant impact of stroke location on 
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depressive symptoms.
42
 Whether tumor laterality plays such a significant role in the severity 
of fatigue, as suggested by our study, remains to be confirmed by future work. 
Similar to previous work, we found that female sex was associated with higher fatigue 
severity at baseline. Recently, Armstrong et al. assessed fatigue in 201 patients with primary 
brain tumors and demonstrated that moderate-severe fatigue was more common in females, 
while low fatigue was more common in males.
5
  
Several limitations of our study have to be acknowledged. First, the included patient 
number was relatively small. Second, drop-out rates at subsequent time points were high and 
might have introduced significant bias. Our observations on evolution of fatigue, sleepiness 
and mood disorders during and after radio-chemotherapy must therefore be considered with 
caution and require confirmation by larger studies with minimal drop-out rates. However, 
elimination of a significant drop-out will be challenging, as it is a well-known, notorious 
problem in longitudinal studies of primary brain tumor patients. Our drop-out rate was 
similar, for instance, to that reported in a very recent large randomized EORTC trial.
43
 Third, 
a certain selection bias is likely, as we included only 60-65% of all eligible glioblastoma 
patients during the study period, which prevents direct generalizability of our findings. 
Finally, we did not measure the impact of fatigue and associated variables on health-related 
quality of life. 
In summary, roughly half of all glioblastoma patients are affected by fatigue at 
postsurgical baseline. Depression is among the strongest predictors of fatigue severity at 
baseline, which might also explain the unexpected absence of increased sleepiness in 
glioblastoma patients. Hence, treating physicians should be more vigilant with regard to 
fatigue and depression in glioblastoma patients, because they both represent frequent co-
morbidities with mutually negative repercussions and they are known to negatively impact 
quality of life, treatment compliance and overall survival.
12,16,18,44
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Figure legends 
 
Figure 1  Frequency and overlap of fatigue and excessive daytime sleepiness in 
glioblastoma  patients and controls. In glioblastoma patients, fatigue is often 
associated with EDS, but «isolated EDS» occurs  seldom.       
 
 
Figure 2 Compared to postsurgical baseline, the scores of the Fatigue Severity Scale 
(FSS), Epworth Sleepiness Scale (ESS), mean bedtimes, HADS-D depression 
and anxiety and Karnofsky Performance Score did not show any significant 
changes during and immediately after combined radio-chemotherapy (RCT). 
Error bars indicate standard deviations. 
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Abstract 
Background. The main goal of this study was to assess frequency, clinical correlates 
and independent predictors of fatigue in a homogenous cohort of well-defined glioblastoma 
patients at baseline prior to combined radio-chemotherapy.  
Methods. We prospectively included 65 glioblastoma patients at postsurgical baseline 
and assessed fatigue, sleepiness, mean bedtimes, mood disturbances and clinical 
characteristics such as clinical performance status, presenting symptomatology, details on 
neurosurgical procedure, tumor location and diameter as well as pharmacologic treatment 
including antiepileptic drugs, antidepressants and use of corticosteroids. Data on fatigue and 
sleepiness were measured with the Fatigue Severity Scale and the Epworth Sleepiness Scale, 
respectively, and compared to 130 age- and sex-matched healthy controls.  
Results. We observed a significant correlation between fatigue and sleepiness scores 
in both patients (r = 0.26, p = 0.04) and controls (r = 0.36, p < 0.001), but only fatigue 
appeared to be much more common in glioblastoma patients then in healthy controls (48% 
vs. 11%, p < 0.001), but not the frequency of sleepiness (22% vs. 19%, p = 0.43). Female sex 
was associated with increased fatigue frequency among glioblastoma patients, but not among 
control subjects. Multiple linear regression analyses identified depression, left-sided tumor 
location and female sex as strongest associates of baseline fatigue severity. 
Conclusions. Our findings indicate that glioblastoma patients are frequently affected 
by fatigue already at baseline, suggesting that factors other than those related to radio- or 
chemotherapy are of significant impact, in particular depression and tumor localization.  
Keywords   Fatigue; glioblastoma; sleepiness; depression 
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Introduction 
Glioblastoma is the most common primary brain tumor in adults, with an estimated 
incidence of about 3 per 100,000 inhabitants / year in Europe and North America.
1
 The 
standard of care for newly diagnosed glioblastoma, subsequent to surgery, comprises 
radiotherapy with concomitant temozolomide followed by adjuvant temozolomide. In the 
study defining this treatment regimen, median survival was limited to 15 months,
2
 and in a 
population-based analysis of more than 10,000 glioblastoma patients, median survival was 
reported to be only 12 months.
3
  
Independent of any treatment, fatigue is a common symptom in cancer patients in 
general as well as in primary brain tumor patients, with an estimated prevalence of 50 to 90% 
and 40 to 70% respectively.
4,5
 Cancer-related fatigue is defined by the National 
Comprehensive Cancer Network (NCCN) as a distressing, persistent, subjective sense of 
physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer 
treatment that is not proportional to recent activity and that interferes with usual functioning.
6
 
The patients themselves indicate fatigue as one of the most distressing symptom related to 
cancer and its treatment,
7
 and it is a strong predictor of decreased patient satisfaction, health-
related quality of life (QoL), and may represent one of the key reason for discontinuing 
treatment.
8-10
 Nevertheless, fatigue is believed to be underdiagnosed and underestimated in 
cancer patients despite its possible impact on treatment compliance.
4,11
 As a consequence, 
some groups have questioned, whether the standard treatment for glioblastoma is justified in 
view of the limited benefit on survival and the severity of associated symptoms.
12
 
However, compared to other tumor types, namely breast and lung cancer, rather few 
studies have addressed the problem of fatigue in glioblastoma patients in depth, and several 
limitations have to be mentioned. First, despite large differences in underlying neurobiology, 
treatment procedures and prognosis, many groups have included patients with all sorts of 
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primary brain tumors.
5,13
 Second, baseline data are often missing, in particular in studies 
using a cross-sectional design.
5
 As a consequence, fatigue was mainly assessed as a treatment 
complication, thereby failing to acknowledge the primary impact of the tumor itself and other 
treatment-independent factors.
14
 Third, considering the advances of modern radiation 
techniques, the results of many older series cannot be directly compared with the current 
situation. Finally, while many validated fatigue questionnaires are available,
9,15
 the large 
majority of neurooncological studies identified and quantified fatigue in a very rudimental 
way, using the Visual Analogue Scale (VAS) or one single fatigue item appearing in tools 
such as the European Organisation for Research and Treatment of Cancer (EORTC) QoL 
questionnaire, the M. D. Anderson Symptom Inventory–Brain Tumor Module or the 
Symptom Distress Scale.
9,12,16-18
 
Thus, in this prospective study we aimed at examining frequency and predictors of 
fatigue severity in a homogeneous cohort of glioblastoma patients at baseline prior to 
combined radio-chemotherapy. For this goal, we used the Fatigue Severity Scale (FSS), 
which has been identified as the most widely adopted fatigue questionnaire in clinical 
practice and has been validated for a variety of neurological diseases.
15,19,20
 In addition, we 
explored the evolution of fatigue, sleepiness and mood disorders during and after combined 
radio-chemotherapy.  
 
Patients and Methods 
  This prospective, longitudinal study was conducted as a collaboration of the 
Departments of Neurology, Oncology and Radiation Oncology of the University Hospital of 
Zurich, Switzerland, between October 2008 and October 2012. The study protocol was 
approved by the Ethics Committee of the Canton of Zurich, Switzerland, specialized 
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subcommittee for Psychiatry, Neurology, Neurosurgery (Project E-43/2007), and informed 
consent was obtained by all patients prior to enrollment. 
Patients and control subjects. We prospectively included 65 patients with newly 
diagnosed and histologically proven glioblastoma, corresponding to an estimated 60-65% of 
all eligible glioblastoma patients of the acquisition period. Patients aged ≥18 years 
undergoing postoperative standard radio-chemotherapy were eligible.
2
 They had to be fluent 
in German language. The patients were examined clinically and by questionnaires at three 
different time points: 1) 28 ± 7 days after the initial neurosurgical procedure (1 day prior to 
the first radiation), 2) at the time of the last radiation and 3) prior to the initiation of the 
adjuvant chemotherapy. Overall, the study period captured the first ten weeks of 
postoperative standard treatment.  
As control group we included 130 healthy and age- and sex-matched subjects using a 
1:2 case-control design. The controls were selected from a previously published cohort of 454 
healthy subjects, which we used in our original validation study of the German version of the 
Fatigue Severity Scale (FSS).
19
 
Clinical assessment and questionnaires. Demographic variables included age, sex and 
educational status (defined as highest degree attained). We ascertained several tumor 
characteristics, including type of neurosurgical procedure (biopsy, partial, complete or 
unclear resection), tumor topography and brain magnetic resonance imaging based tumor 
diameter. To elucidate whether the presenting symptomatology affects fatigue severity, we 
divided the medical history in seizure, motor weakness, cognitive deficit, 
headache/nausea/vomiting, apathy/asthenia, visual deficit, and accidental finding. Seizure 
type was further classified in partial, generalized, complex-focal, and unclassified. To 
estimate the influence of pharmacological treatment, we included at each time point details 
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on anticonvulsive drugs, antidepressants, anxiolytics, CNS stimulants, hypnotics, and 
whether or not patients received corticosteroids, including the dose of the steroids. Clinical 
performance status was assessed by the Karnofsky Performance Score (KPS), with 100% 
indicating perfect physical health and 0% death. As mentioned earlier, we measured fatigue 
by means of the FSS. This self-administered questionnaire comprises 9 items exploring 
fatigue severity in different situations during the past week, and the final score ranges from 1 
to 7, with the latter value indicating maximal fatigue. The presence of clinically significant 
fatigue was defined as a FSS score ≥ 4.0. The FSS has robust psychometric properties and 
has been validated for various neurological disorders but not yet for glioblastoma patients. 
We therefore performed a reliability statistic in our cohort, revealing an excellent internal 
consistency as reflected by a Cronbach’s α of 0.94.21 We used the German version of the 
Epworth Sleepiness Scale (ESS) for assessment of sleepiness; a score of ≥ 10 indicates 
EDS.
22
 We also determined the prevalence of overlap between fatigue and EDS, which was 
the case when patients presented both a FSS score ≥ 4.0 and an ESS score ≥ 10. Sleep need 
was estimated using information on mean bed times. We arbitrarily defined mean bedtimes ≥ 
10 hours as “long bedtimes”, probably indicating increased sleep need per 24 hours (i.e. 
hypersomnia). Finally, for evaluation of anxiety and depression, we used the German version 
of the Hospital Anxiety and Depression Scale (HADS). It is a well-validated questionnaire 
suitable for cancer populations as it contains only nonphysical symptoms of both anxiety and 
depression. Participants indicate their agreement with each item on a scale ranging from 0 to 
3. The questionnaire has two subscales for anxiety and depression, each consisting of 7 items. 
A score of > 10 is considered to indicate overt anxiety or depression.
23,24
 
Data analysis and statistics. We used SPSS (version 19.0) for statistical analysis. 
Group data are described by means, standard deviations (SD), and confidence intervals (95% 
CI). To compare mean values of FSS and ESS scores between glioblastoma patients and 
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control subjects, we used Student’s t test; χ2-test was used to compare the frequency of 
fatigue and EDS between the two groups. Longitudinal differences of scores were assessed 
using Student’s paired t test. We applied the Cronbach α statistics to calculate the internal 
consistency of the FSS in glioblastoma patients. To identify predictors of fatigue severity at 
baseline, we performed a multiple linear regression analysis with FSS score as dependent 
variable. Among the set of potential predictor variables (age, gender, education, KPS, ESS, 
bedtimes, anxiety and depression scores, tumor localization and use of steroids or 
antidepressants), we evaluated each variable for an estimated effect of ≥ 0.2 or ≤ -0.2 on the 
outcome score fatigue severity and a p-value < 0.05 in a univariate comparison. Those 
predictor variables fulfilling the two criteria were included in the multiple linear regression 
model. Significance was accepted at p < 0.05. 95% confidence intervals (CI) for mean 
differences between the groups were additionally presented when group differences were 
significantly different from zero. 
 
Results 
  Characterization of glioblastoma patients. We included 65 glioblastoma patients, of 
whom 44 patients (68%) were male. Mean age was 57.3 ± 10.1 years. The tumor was 
localized in the left brain hemisphere in 28 patients (43%), in the right hemisphere in 31 
patients (48%), and bilateral in 6 patients (9%). A majority of tumors affected the fronto-
temporal lobes (57%) as compared to the parieto-occipital lobes (31%), basal ganglia (5%) or 
multiple sites (8%). 
Comparison between glioblastoma patients and controls. Glioblastoma patients had 
significantly higher FSS scores (3.9 ± 1.7 vs. 2.8 ± 1.0, 95% CI 0.74 - 1.49, p < 0.001) and 
fatigue frequency (48% vs. 11%, p < 0.001), and significantly longer bedtimes (8.8 ± 1.2h vs. 
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7.7 ± 0.9h, 95% CI 0.76 - 1.39, p < 0.001) than controls, whereas ESS scores and the 
prevalence of EDS was similar (Table 1). FSS and ESS scores were significantly correlated 
in both glioblastoma patients (r = 0.26, p = 0.04) and control subjects (r = 0.36, p < 0.001). In 
glioblastoma patients, overlap of both fatigue and EDS was observed in 15%, while “isolated 
fatigue” was much more common (32%) than “isolated EDS” (6%) (Fig. 1). Conversely, we 
observed more controls with “isolated EDS” (14%) than “isolated fatigue” (5%) (p < 0.001).  
Comparison of glioblastoma patients with and without fatigue. Prior to radiotherapy, 
almost half of all glioblastoma patients suffered from fatigue. Compared to those without 
fatigue, glioblastoma patients with fatigue revealed a higher prevalence of EDS (32% vs. 
12%, p = 0.04), spent more time in bed (95% CI 0.13 - 1.32, p = 0.02) and were more 
depressed (95% CI 0.78 - 4.04, p = 0.005) (Table 2). In addition, gender distribution differed 
significantly: of totally 21 female glioblastoma patients, 14 had fatigue (67%), while only 
39% of all male patients had fatigue (p = 0.03). Of note, fatigue prevalence was similar in 
female and male controls (12% vs. 10%, p = 0.49). Finally, glioblastoma patients affected by 
a tumor in the left brain hemisphere appeared to suffer more frequently from fatigue than 
those with right-sided tumors (Table 3). Patients with left-sided tumor localization were also 
more prone to anxiety and depression. On the other hand, we did not observe any group 
differences concerning educational status, presenting symptomatology, seizure type, use of 
antiepileptic drugs or corticosteroids nor extent of tumor resection.      
Predictors of fatigue severity in glioblastoma patients. Using a multiple linear regression 
model, we identified higher HADS-D depression score (estimated effect = 0.16 per one unit 
increase in depression score, p = 0.004), left-sided tumor location (estimated effect = -0.88, p 
= 0.002) and female sex (estimated effect 0.89, p = 0.02) as significant associates of fatigue 
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severity at baseline prior to radio-chemotherapy (Table 4). The adjusted r-squared and the 
multiple r-squared of our final model were 0.29 and 0.32, respectively.  
Evolution of fatigue, EDS and mood disorders. Unfortunately, drop-out rate was 
rather high: of the included 65 GBM patients, only 46 and 38 patients filled out all 
questionnaires during and after radio-chemotherapy, respectively. Mean values for FSS and 
ESS scores, mean bedtimes, anxiety and depression scores of the HADS-D and KPS did not 
show significant changes at subsequent time points (Fig. 2).  
 
Discussion 
Our prospective study demonstrates that fatigue is a prominent pre-treatment 
symptom in patients with newly diagnosed and operated glioblastoma, reaching a prevalence 
of 48% compared to only 11% among healthy control subjects. Surprisingly, our data 
represent the first controlled assessment of fatigue frequency in a selected and homogeneous 
cohort of glioblastoma patients, and measured with a specific and validated fatigue 
questionnaire. Although direct comparison is obviously hampered by major methodological 
differences, our finding roughly matches the reported 40-70% fatigue prevalence among 
patients with primary brain tumors.
5,9,14
 On the other hand, we had found higher fatigue 
prevalence in patients with other neurological disorders such as multiple sclerosis (69%), 
idiopathic Parkinson’s disease (59%), episodic migraine (54%, unpublished data) or previous 
ischemic stroke (49%), always using the FSS.
19,20
  
Fatigue in patients with primary brain tumors has repeatedly been reported in relation 
to radiotherapy.
13,25,26
 In contrast, our study challenges the view that fatigue in glioblastoma 
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patients represents mainly a complication of radio- and / or chemotherapy, because the 
prevalence of fatigue was highly already prior to radio-chemotherapy. Therefore, the 
contribution of toxicity from radio-chemotherapy to fatigue is probably only one single factor 
among many others. In addition, the longitudinal assessment of fatigue, sleepiness and mood 
disturbances during and after radio-chemotherapy did not show significant changes, which 
might reflect, however, a bias due to the high drop-out rate. On the other hand, it’s 
conceivable that the toxic effect of radio-chemotherapy on fatigue severity was obscured in 
our cohort by the additional presence of many other fatigue-inducing factors. Of related 
interest is our observation that pharmacological treatment, including antiepileptic drugs, 
antidepressants or corticosteroids, was not associated with fatigue. This is in contrast to a 
recent work of Struik et al., who reported an increase of fatigue severity under antiepileptic 
drugs and corticosteroids among patients with low-grade glioma.
27
  
While fatigue was more than 4times more prevalent in glioblastoma patients than in 
control subjects, the frequency of excessive daytime sleepiness was similar (22% vs. 19%). 
Fatigue and sleepiness are commonly regarded as two distinct symptoms, but they present 
substantial overlap and presumably, at least to some extent, also similar pathophysiology.
28
 
Our finding is surprising, because increased frequency of sleepiness is indeed common in 
many neurological disorders with prominent fatigue. For instance, we found excessive 
daytime sleepiness in 48% of patients with idiopathic Parkinson’s disease and 38% of 
traumatic brain injury survivors, while other groups reported an even higher prevalence.
20,29
 
Degenerative or trauma-induced disruption of arousal-promoting structures in the rostral 
brainstem and hypothalamus may cause both fatigue and sleepiness, and this assumption is 
increasingly supported by neuropathological evidence.
30-32
 On the other hand, fatigue is a 
complex symptom, influenced by a large variety of factors, and the composition of these 
contributing factors differs most likely between neurological disorders commonly associated 
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with high fatigue burden. Thus, it’s tempting to speculate whether the selective increase of 
fatigue but normal prevalence of sleepiness may shed some light on the underlying etiology 
of glioblastoma-related fatigue. Of interest in this context, the discrepant prevalence of 
fatigue and sleepiness is reminiscent of patients with mood disorders, who often suffer from 
fatigue and insomnia, while sleepiness is not a consistent complaint.
33
 In the same line, using 
multiple regression analyses we could identify depression as independent predictor of fatigue 
severity at baseline. To the best of our knowledge, this is the first study to highlight this 
important association between fatigue severity and depression in glioblastoma patients, while 
similar correlations have been reported in breast cancer patients but never in patients with 
primary brain tumors.
34,35
  
Anxiety and depression represent normal emotional reactions to the diagnosis of 
glioblastoma, and they are significant and independent contributors to fatigue severity. 
However, as emphasized by the overview of Litofsky and Resnick and further corroborated 
by our observations, other factors have to be considered.
36
 Of note, fatigue, anxiety and 
depression all appeared to be more common in glioblastoma patients with left-sided tumors 
compared to those with right-sided tumors, and left-sided tumor location was consistently 
identified as independent predictor of fatigue severity. Indeed, there is some evidence 
indicating that patients with left hemispheric lesions are prone to depressive reactions, 
whereas patients with right hemisphere lesions often show indifferent emotional 
reactions.
33,38,39
 Likewise, Klein et al. found significant impairment of attentional and 
executive functioning in patients with left-sided high-grade glioma compared to right-sided.
40
 
However, several studies failed to observe any association between depression and 
hemispheric laterality of gliomas.
41
 Data on depression in ischemic stroke provide a similarly 
inconsistent picture. Few studies suggested a higher prevalence of depression in left-sided 
ischemic stroke, but other studies could not confirm a significant impact of stroke location on 
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depressive symptoms.
42
 Whether tumor laterality plays such a significant role in the severity 
of fatigue, as suggested by our study, remains to be confirmed by future work. 
Similar to previous work, we found that female sex was associated with higher fatigue 
severity at baseline. Recently, Armstrong et al. assessed fatigue in 201 patients with primary 
brain tumors and demonstrated that moderate-severe fatigue was more common in females, 
while low fatigue was more common in males.
5
  
Several limitations of our study have to be acknowledged. First, the included patient 
number was relatively small. Second, drop-out rates at subsequent time points were high and 
might have introduced significant bias. Our observations on evolution of fatigue, sleepiness 
and mood disorders during and after radio-chemotherapy must therefore be considered with 
caution and require confirmation by larger studies with minimal drop-out rates. However, 
elimination of a significant drop-out will be challenging, as it is a well-known, notorious 
problem in longitudinal studies of primary brain tumor patients. Our drop-out rate was 
similar, for instance, to that reported in a very recent large randomized EORTC trial.
43
 Third, 
a certain selection bias is likely, as we included only 60-65% of all eligible glioblastoma 
patients during the study period, which prevents direct generalizability of our findings. 
Finally, we did not measure the impact of fatigue and associated variables on health-related 
quality of life. 
In summary, roughly half of all glioblastoma patients are affected by fatigue at 
postsurgical baseline. Depression is among the strongest predictors of fatigue severity at 
baseline, which might also explain the unexpected absence of increased sleepiness in 
glioblastoma patients. Hence, treating physicians should be more vigilant with regard to 
fatigue and depression in glioblastoma patients, because they both represent frequent co-
morbidities with mutually negative repercussions and they are known to negatively impact 
quality of life, treatment compliance and overall survival.
12,16,18,44
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Figure legends 
 
Figure 1  Frequency and overlap of fatigue and excessive daytime sleepiness in 
glioblastoma  patients and controls. In glioblastoma patients, fatigue is often 
associated with EDS, but «isolated EDS» occurs  seldom.       
 
 
Figure 2 Compared to postsurgical baseline, the scores of the Fatigue Severity Scale 
(FSS), Epworth Sleepiness Scale (ESS), mean bedtimes, HADS-D depression 
and anxiety and Karnofsky Performance Score did not show any significant 
changes during and immediately after combined radio-chemotherapy (RCT). 
Error bars indicate standard deviations. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Comparison of frequency and severity of fatigue, sleepiness and mean 
bedtimes between glioblastoma patients and controls. Values are mean ± 
standard deviation. 
 
   Glioblastoma   Controls  p 
   patients (n = 65)  (n = 130) 
Age [y]   57.3 ± 10.1   57.4 ± 9.8  0.93 
Gender, male   44 (68%)   88 (68%)  0.57 
FSS   3.9 ± 1.7   2.8 ± 1.0          <0.001 
Fatigue (FSS >4.0)  31 (48%)   14 (11%)          <0.001 
ESS   5.9 ± 4.3   6.2 ± 3.6  0.67 
EDS (ESS > 10)  14 (22%)   25 (19%)  0.43 
Mean bedtime [h]  8.8 ± 1.2   7.7 ± 0.9          <0.001 
Long bedtime (>10h)  10 (16%)   4 (3%)             0.003 
 
 
EDS:  excessive daytime sleepiness      
ESS:  Epworth Sleepiness Scale      
FSS:  Fatigue Severity Scale      
 
 
 
Table
Table 2 Comparison of glioblastoma patients with and without fatigue at baseline. Data 
are described as mean ± standard deviation. 
Glioblastoma patients Glioblastoma patients 
                                    with fatigue (n = 31) without fatigue (n = 34)   p 
Age [y]   57.4 ± 10.6  57.2 ± 9.7   0.94 
Male : Female   17 (55%) : 14 (45%) 27 (79%) : 7 (21%)         0.03 
KPS   82.2 ±15.1  85.5 ± 11.3   0.36 
Tumor diameter [cm]  4.0 ± 1.5  4.0 ± 1.5   0.84  
Tumor localization                0.03 
Left   19 (61%)    9 (26%) 
Right   12 (39%)  19 (56%) 
Bilateral     0      6 (18%) 
Tumor topography         0.59 
Fronto-temporal  20   17 
Parieto-occipital    7   13 
Basal ganglia     1     2 
Fronto-temporal +    3     1 
   parieto-occ. 
Parieto-occ. +     0     1 
   basal ganglia 
Presenting symptomatology        0.18 
Table
2 
 
Seizure   15    15 
Motor weakness    5      7 
Cognitive deficit    8      7 
Headache, nausea, vomiting   8      5 
Apathy, asthenia    0      2 
Visual deficit     0      3 
Accidental finding    0      1 
Seizure type          0.63 
No seizure     6    12    
Partial     4      5 
Generalized     9      8 
Complex-focal    2      0 
Unclassified     1      1 
Partial + generalized    2      3 
Complex-focal + generalized   0      1 
Antiepileptic drugs  19    22   0.49 
Levetiracetam     9    12   
Phenytoin     9      7    
Clobazam     5      6    
Lamotrigin     2      3    
Clonazepam     1      0    
Topiramat     1      0    
Gabapentin     0      2    
Valproat     1      1    
3 
 
Extent of resection         0.74 
Biopsy     2      4 
Partial   22    20   
Complete     6      8 
Unclear     1      2 
ESS score   7.1 ± 4.9   4.8 ± 3.4    0.03 
EDS (ESS score >10)  10 (32%)   4 (12%)          0.04 
Mean bedtime [h]  9.2 ± 1.2   8.5 ± 1.1    0.02 
Long bedtime (>10h)  6 (19%)   4 (12%)  0.25 
Anxiety score   6.2 ± 4.0   5.3 ± 3.7    0.32 
Anxiety, prevalence  7 (23%)   4 (18%)          0.20 
Depression score  5.7 ± 3.5   3.3 ± 3.1            0.005 
Depression, prevalence 4 (13%)   2 (6%)   0.29 
Corticosteroids [mg]  2.7 ± 3.7   2.5 ± 2.7  0.79 
Activating antidepressants 3    2   0.46 
Sedating antidepressants 1    1   0.73 
Anxiolytics   0    0 
CNS stimulants  0    0 
Hypnotics   1    2   0.54 
 
 
 
 
EDS: excessive daytime sleepiness      ESS: Epworth Sleepiness Scale      
FSS: Fatigue Severity Scale      KPS: Karnofsky performance status 
Table 3 Comparison of fatigue, sleepiness and mood disorders between patients with 
left- and right-sided glioblastoma at baseline prior to radio-chemotherapy. 
Data are described as mean ± standard deviation. 
 
 
    Left-sided tumor Right-sided tumor p 
    (n = 28)  (n = 31) 
Age [y]    55.8 ± 9.5  57.9 ± 10.5  0.43 
Gender, male    20 (71%)  21 (68%)  0.60 
Karnofsky performance status 86 ± 14  83 ± 12  0.40 
Tumor diameter [cm]   4.0 ± 1.7  4.0 ± 1.3  0.92 
FSS    4.6 ± 1.3  3.5 ± 1.8            0.008 
Fatigue (FSS >4.0)   19 (68%)  12 (39%)            0.004 
ESS    5.8 ± 4.2  6.0 ± 4.7  0.83 
EDS (ESS >10)   5 (18%)  8 (26%)  0.73 
Mean bedtime [h]   9.1 ± 1.4  8.6 ± 1.0  0.13 
Long bedtime (>10h)   7 (25%)  3 (11)   0.18 
Anxiety, HADS-D   6.6 ± 3.8  5.1 ± 4.0  0.16 
Anxiety (prevalence)   8 (30%)  3 (10%)  0.03 
Depression, HADS-D  5.3 ± 2.9  3.6 ± 3.8  0.05 
Depression, prevalence  2 (9%)   4 (13%)  0.49 
 
EDS:  excessive daytime sleepiness      
ESS:  Epworth Sleepiness Scale               
FSS:  Fatigue Severity Scale   
HADS-D:  Hospital Anxiety and Depression Scale, German version 
Table
Table 4 Multiple linear regression model for coefficients of fatigue severity at baseline in glioblastoma patients.  
    
Dependent   Significant     Estimated Standard t value  p 
variable   coefficients 
*
     effect  error 
 
FSS score (baseline)   HADS-D score for depression  0.16  0.05  3.03  0.004 
Tumor localization [left]   0.88       0.28            3.16  0.002    
Female sex     0.89  0.38  2.38  0.020 
 
*
 Additional coefficients included in the model were age, education, Karnofsky Performance Score, Epworth Sleepiness Scale, bedtimes, HADS-
D score for anxiety, use of steroids, and use of antidepressants. 
FSS:  Fatigue Severity Scale   
HADS-D:  Hospital Anxiety and Depression Scale, German version 
Table
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